Abstract
Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 301-308 |
| Number of pages | 8 |
| Journal | American Journal of Clinical Pathology |
| Volume | 147 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 1 2017 |
Fingerprint
Keywords
- barrett carcinogenesis
- gastric adenocarcinoma
- microRNA
- preneoplastic lesions
ASJC Scopus subject areas
- Pathology and Forensic Medicine
Cite this
Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. / Fassan, Matteo; Saraggi, Deborah; Balsamo, Laura; Realdon, Stefano; Scarpa, Marco; Castoro, Carlo; Coati, Irene; Salmaso, Roberta; Farinati, Fabio; Guzzardo, Vincenza; Arcidiacono, Diletta; Munari, Giada; Gasparini, Pierluigi; Veronese, Nicola; Luchini, Claudio; Valeri, Nicola; Rugge, Massimo.
In: American Journal of Clinical Pathology, Vol. 147, No. 3, 01.03.2017, p. 301-308.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early miR-223 Upregulation in Gastroesophageal Carcinogenesis
AU - Fassan, Matteo
AU - Saraggi, Deborah
AU - Balsamo, Laura
AU - Realdon, Stefano
AU - Scarpa, Marco
AU - Castoro, Carlo
AU - Coati, Irene
AU - Salmaso, Roberta
AU - Farinati, Fabio
AU - Guzzardo, Vincenza
AU - Arcidiacono, Diletta
AU - Munari, Giada
AU - Gasparini, Pierluigi
AU - Veronese, Nicola
AU - Luchini, Claudio
AU - Valeri, Nicola
AU - Rugge, Massimo
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
AB - Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
KW - barrett carcinogenesis
KW - gastric adenocarcinoma
KW - microRNA
KW - preneoplastic lesions
UR - http://www.scopus.com/inward/record.url?scp=85017484422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017484422&partnerID=8YFLogxK
U2 - 10.1093/ajcp/aqx004
DO - 10.1093/ajcp/aqx004
M3 - Article
C2 - 28395057
AN - SCOPUS:85017484422
VL - 147
SP - 301
EP - 308
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
SN - 0002-9173
IS - 3
ER -